Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 2025Frontiers in OncologyOpen Access

Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

BXBai XuexueCYChengrui YanWMWenbin Ma

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows MGMT and IDH status influences survival in patients with high-grade glioma, suggesting biomarker testing enhances treatment strategies.

Key Points

  • Patients with MGMT methylation and IDH mutations experienced increased progression-free survival and overall survival.
  • Overall survival rates were significantly better for the MGMT methylated group compared to the unmethylated group in this cohort.
  • Cox regression analysis identified MGMT and IDH as independent prognostic factors alongside tumor grade and resection extent.
  • The study suggests incorporating MGMT and IDH status into treatment decisions for patients with high-grade glioma receiving bevacizumab.

Cite This Study

Xuexue et al. (2025) studied this question.

synapsesocial.com/papers/68af7b1f7567bf4f94ff2dachttps://doi.org/10.3389/fonc.2025.1634892
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma2025
  2. 2Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma2025
  3. 3IDH wild-type glioblastoma: Predictive value of standard-of-care (SOC) MRI for establishing MGMT promoter methylation status2025 · 1 citations
  4. 4The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma2025 · 4 citations
  5. 5MOLECULAR MARKERS IN PREDICTING THE OUTCOME OF DIFFUSE GLIOMA GRADE 4 TREATMENT2025